ESTRO 2025 - Abstract Book

S996

Clinical – Head & neck

ESTRO 2025

1866

Digital Poster Photobiomodulation in head and neck cancer patients undergoing chemoradiotherapy: role in toxicities prevention, update data Margherita Rotondi 1,2 , Giuseppe Facondo 3 , Andreea Cabulca 2 , Nahla Belattar 2 , Gabriela Dumitriescu 2 , Eric Deutsch 2,4 , Camelia Billard-Sandu 2 1 Radiation Oncology, Azienda Sanitaria Universitaria, Trieste, Italy. 2 Oncology-Radiotherapy, Gustave Roussy, Villejuif, France. 3 Radiation Oncology, Azienda Sanitaria Universitaria, Udine, Italy. 4 Radiothérapie Molèculaire et Innovation Thérapeutique, INSERM, Villejuif, France Purpose/Objective: To evaluate effect of photobiomodulation-therapy (PBMT) in preventing and reducing chemoradiotherapy-induced toxicities in a larger cohort of head and neck cancer (HNC) patients. Material/Methods: Between May 2021 and July 2024 we retrospectively analyzed 119 patients (pts) with HNC treated with chemoradiotherapy (CRT) in adjuvant or definitive intent and concomitant PBM. The ATP38 device with different treatment protocols was used based on clinical indication (Tab.1). The median number of sessions was 10 (IQR,8-13 sessions) and the population was divided into two groups: group-A (PBM<10 sessions) 44pts (36.97%), group-B (PBM≥10 sessions) 75 pts (63.02%). The main toxicities were assessed according to the CTCAE v5.0 at the half of PBMT (T1), at the end of PBMT (T2), during follow up at 3 months (T3) and at the last medical record (T4). It was considered also the weight-loss between T2 and T0 (start CRT); osteonecrosis and dysphonia (excluding laryngeal primary) at T4. The chi-square test was used to evaluate the association between PBM sessions and toxicity. Logistic regression was used for continuous variables. Analysis of dependent variable "weigh” was performed with a 1-tailed t-test comparing to the time of PBM (T0-T2). The Kaplan–Meier method was used to estimate the rates survival analysis.

Results: The median age was 59years (IQR,53-66years), most common primary tumour was squamous carcinoma (90.8%), the median follow-up was 13months (IQR8-17months). None had G4 toxicity. At T4 osteonecrosis and dysphonia was detected in 5.88% and 2.85% of patients, respectively. The weight-loss (T2-T0) was statistically significant with a p-value of <0.01 (median4.98;std4.02; 95CI:4.08-5.87). The analyses of xerostomia at T2 continue variables shows significantly with a p-value of 0.05 (OR1.11;CI:1-1.23) in the yes/no toxicities category and at T4 the analyses of xerostomia shows significantly with a p-value of 0.05 in the G0-1/G2-3 toxicities category: group-B developed significantly fewer ≥G2 toxicities compared to Group-A. The analyses of dysphagia at T2 and T4 was statistically significant in both categories (Tab.2). The median local control, metastasis free survival, disease-free survival and overall survival at 6months and 12months were, respectively: 96% and 93.4%, 93.4% and 91.8%, 91.5% and 87.5%, 99% and 97.9%.